人类表皮生长因子受体2的改变和预后影响在乳腺癌的所有亚型的乳腺癌
Arielle L Heeke1, Andrew Elliott2, Kaitlyn O'Keefe1
1Levine Cancer Institute, Atrium Health, Charlotte, NC.
JCO precision oncology
|January 31, 2025
概括
人类表皮生长因子受体2 (HER2) 基因的改变,包括突变和融合,存在于各种乳腺癌亚型中. 这些HER2变化与更差的预后有关,特别是在转移性和叶状乳腺癌中.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 人类表皮生长因子受体2 (HER2) 基因 (ERBB2) 在细胞生长中起着至关重要的作用,是特定癌症治疗的目标.
- 了解乳腺癌ERBB2变化的范围对于指导治疗决策和预测患者的结果至关重要.
研究的目的:
- 在各种乳腺癌亚型中全面描述ERBB2变化的频率和类型 (突变,融合,拷贝数放大).
- 研究ERBB2变化与临床病理特征之间的关联,包括瘤组织学和转移状态.
- 探索ERBB2改变对乳腺癌患者整体存活期 (OS) 的预后意义.
主要方法:
- 来自12,153个乳腺癌样本的下一代测序 (DNA和RNA) 数据的回顾性分析.
- 识别和分类ERBB2突变,融合和副本数量的变化.
- ERBB2改变与临床病理特征和HER2状态 (包括HER2-低) 的相关性.
- 使用Kaplan-Meier估计的生存分析,对具有可用结局数据的患者进行生存分析.
主要成果:
- 在3.2%的瘤中发现了致病性ERBB2突变 (ERBB2-mut),肝转移 (5.7%) 和叶状乳腺癌 (10%) 的患病率更高.
- ERBB2合并很少发生 (0.3%). 与三阴性乳腺癌相比,ERBB2-mut在HER2-阳性/低瘤中更常见.
- ERBB2-mut与CDH1 (40.0%) 和ERBB3 (10.6%) 的共同变化有显著关联,并且与整体存活率较差相关.
结论:
- 在所有乳腺癌亚型中发生ERBB2突变和融合,特别是在HER2+/低,转移性和叶片瘤中.
- 存在ERBB2突变与乳腺癌患者的预后较差有关.
- 这些发现强调了 ERBB2 变化的特征对于向治疗选择和预后评估的临床相关性.
相关概念视频
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
The Ras Gene
6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.1K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K


